XCancer

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Description:

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Sponsor:

Endocyte

Phase:

Phase 2

Contacts:

Nelson M Oyesiku, MD, PhD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01684098 - Click here to see study on

ClinicalTrials.gov

EC20

Isotope(s):
Target(s):
  • FR (Folate Receptor)
Ligand Class: Small Molecules
Inclusion
  • Patient must have known or strongly suspected recurrent or metastatic cancer from a solid tumor with at least one identifiable lesion \> 1.5 cm as diagnosed by conventional imaging.
  • Patient must have adequate liver function defined as transaminases (SGOT and/or SGPT) may be up to 2.5 X ULN if alkaline phosphatase is \<ULN or alkaline phosphatase may be up to 2.5 X ULN if Transaminases are \< ULN. If alkaline phosphatase is outside of these parameters and is due to bone metastases verified by assessment of isoenzymes, then the subject is eligible.
  • Patient must have adequate kidney function defined as serum creatinine of \< 1.5 X ULN.
  • Patient must be 18 years of age or older.
  • * Patients must meet the following eligibility requirements to be enrolled in the study:
Exclusion
  • Patient is simultaneously participating in another investigational drug study, excluding the follow-up phase.
  • Patient has received an investigational agent within 7 days prior to enrollment.
  • * Patients must be excluded in any of the following conditions are present:
  • Patient is pregnant or breastfeeding.
  • Patient is unable to tolerate conditions for radionuclide imaging.